200 related articles for article (PubMed ID: 16634636)
1. The achondroplasia mutation does not alter the dimerization energetics of the fibroblast growth factor receptor 3 transmembrane domain.
You M; Li E; Hristova K
Biochemistry; 2006 May; 45(17):5551-6. PubMed ID: 16634636
[TBL] [Abstract][Full Text] [Related]
2. Effect of pathogenic cysteine mutations on FGFR3 transmembrane domain dimerization in detergents and lipid bilayers.
You M; Spangler J; Li E; Han X; Ghosh P; Hristova K
Biochemistry; 2007 Oct; 46(39):11039-46. PubMed ID: 17845056
[TBL] [Abstract][Full Text] [Related]
3. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and forster resonance energy transfer suggest weak interactions between fibroblast growth factor receptor 3 (FGFR3) transmembrane domains in the absence of extracellular domains and ligands.
Li E; You M; Hristova K
Biochemistry; 2005 Jan; 44(1):352-60. PubMed ID: 15628877
[TBL] [Abstract][Full Text] [Related]
4. FGFR3 dimer stabilization due to a single amino acid pathogenic mutation.
Li E; You M; Hristova K
J Mol Biol; 2006 Feb; 356(3):600-12. PubMed ID: 16384584
[TBL] [Abstract][Full Text] [Related]
5. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia.
Webster MK; Donoghue DJ
EMBO J; 1996 Feb; 15(3):520-7. PubMed ID: 8599935
[TBL] [Abstract][Full Text] [Related]
6. Effect of the achondroplasia mutation on FGFR3 dimerization and FGFR3 structural response to fgf1 and fgf2: A quantitative FRET study in osmotically derived plasma membrane vesicles.
Sarabipour S; Hristova K
Biochim Biophys Acta; 2016 Jul; 1858(7 Pt A):1436-42. PubMed ID: 27040652
[TBL] [Abstract][Full Text] [Related]
7. Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization.
Adar R; Monsonego-Ornan E; David P; Yayon A
J Bone Miner Res; 2002 May; 17(5):860-8. PubMed ID: 12009017
[TBL] [Abstract][Full Text] [Related]
8. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia.
Naski MC; Wang Q; Xu J; Ornitz DM
Nat Genet; 1996 Jun; 13(2):233-7. PubMed ID: 8640234
[TBL] [Abstract][Full Text] [Related]
9. Neutron diffraction studies of fluid bilayers with transmembrane proteins: structural consequences of the achondroplasia mutation.
Han X; Mihailescu M; Hristova K
Biophys J; 2006 Nov; 91(10):3736-47. PubMed ID: 16950849
[TBL] [Abstract][Full Text] [Related]
10. Ser217Cys mutation in the Ig II domain of FGFR3 in a Chinese family with autosomal dominant achondroplasia.
Zhang SR; Zhou XQ; Ren X; Wang TT; Yuan MX; Wang Q; Liu JY; Liu MG
Chin Med J (Engl); 2007 Jun; 120(11):1017-9. PubMed ID: 17624273
[No Abstract] [Full Text] [Related]
11. Predominance of the mutation at 1138 of the cDNA for the fibroblast growth factor receptor 3 in Japanese patients with achondroplasia.
Tonoki H; Nakae J; Tajima T; Shinohara N; Monji J; Satoh S; Fujieda K
Jpn J Hum Genet; 1995 Dec; 40(4):347-9. PubMed ID: 8851771
[TBL] [Abstract][Full Text] [Related]
12. Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia.
Rousseau F; Bonaventure J; Legeai-Mallet L; Pelet A; Rozet JM; Maroteaux P; Le Merrer M; Munnich A
Nature; 1994 Sep; 371(6494):252-4. PubMed ID: 8078586
[TBL] [Abstract][Full Text] [Related]
13. Direct assessment of the effect of the Gly380Arg achondroplasia mutation on FGFR3 dimerization using quantitative imaging FRET.
Placone J; Hristova K
PLoS One; 2012; 7(10):e46678. PubMed ID: 23056398
[TBL] [Abstract][Full Text] [Related]
14. NMR-based approach to measure the free energy of transmembrane helix-helix interactions.
Mineev KS; Lesovoy DM; Usmanova DR; Goncharuk SA; Shulepko MA; Lyukmanova EN; Kirpichnikov MP; Bocharov EV; Arseniev AS
Biochim Biophys Acta; 2014 Jan; 1838(1 Pt B):164-72. PubMed ID: 24036227
[TBL] [Abstract][Full Text] [Related]
15. FGFR3 targeting strategies for achondroplasia.
Laederich MB; Horton WA
Expert Rev Mol Med; 2012 Jan; 14():e11. PubMed ID: 22559284
[TBL] [Abstract][Full Text] [Related]
16. A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia.
Bellus GA; McIntosh I; Smith EA; Aylsworth AS; Kaitila I; Horton WA; Greenhaw GA; Hecht JT; Francomano CA
Nat Genet; 1995 Jul; 10(3):357-9. PubMed ID: 7670477
[TBL] [Abstract][Full Text] [Related]
17. Identification and in silico characterization of p.G380R substitution in FGFR3, associated with achondroplasia in a non-consanguineous Pakistani family.
Ajmal M; Mir A; Shoaib M; Malik SA; Nasir M
Diagn Pathol; 2017 Jul; 12(1):47. PubMed ID: 28679403
[TBL] [Abstract][Full Text] [Related]
18. Studies of receptor tyrosine kinase transmembrane domain interactions: the EmEx-FRET method.
Merzlyakov M; Chen L; Hristova K
J Membr Biol; 2007 Feb; 215(2-3):93-103. PubMed ID: 17565424
[TBL] [Abstract][Full Text] [Related]
19. Physical basis behind achondroplasia, the most common form of human dwarfism.
He L; Horton W; Hristova K
J Biol Chem; 2010 Sep; 285(39):30103-14. PubMed ID: 20624921
[TBL] [Abstract][Full Text] [Related]
20. Reduced binding of FGF1 to mutant fibroblast growth factor receptor 3.
Khnykin D; Olsnes S
Growth Factors; 2006 Jun; 24(2):111-9. PubMed ID: 16801131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
